Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： A,Di Federico

第一单位： Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston.

作者： A,Di Federico ^[1] ; S L,Alden ^[2] ; J W,Smithy ^[3] ; B,Ricciuti ^[1] ; J V,Alessi ^[1] ; X,Wang ^[4] ; F,Pecci ^[1] ; G,Lamberti ^[1] ; M M,Gandhi ^[1] ; V R,Vaz ^[1] ; L F,Spurr ^[5] ; L M,Sholl ^[6] ; K L,Pfaff ^[7] ; S J,Rodig ^[6] ; Y Y,Li ^[8] ; A D,Cherniack ^[8] ; M,Nishino ^[9] ; B E,Johnson ^[1] ; M M,Awad ^[10]

作者单位： Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston. ^[1] Johns Hopkins School of Medicine, Baltimore. ^[2] Memorial Sloan Kettering Cancer Center, New York. ^[3] Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston. ^[4] Pritzker School of Medicine, University of Chicago, Chicago; Department of Radiation and Cellular Oncology, University of Chicago, Chicago. ^[5] Department of Pathology, Brigham and Women's Hospital, Boston. ^[6] Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston. ^[7] Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston; Cancer Program, Broad Institute of MIT and Harvard, Cambridge. ^[8] Department of Radiology, Brigham and Women's Hospital, Boston; Department of Imaging, Dana-Farber Cancer Institute, Boston, USA. ^[9] Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston. Electronic address: mark_awad@dfci.harvard.edu. ^[10]

关键词 PD-L1 TMB immunotherapy non-small-cell lung cancer tumor genomics variations